Other substances

WNbFc 15

An anti-Spike (SARS-CoV-2) nanobody construct.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

WNbFc 15 is a bivalent fusion nanobody-Fc construct potently neutralizing SARS-CoV-2. It displays binding of E484K or N501Y variants of Spike protein. It also inhibits RBD binding to ACE2 in vitro. Prophylactic administration of the nanobody construct significantly reduced viral loads in mice in a viral challenge. The original nanobodies were identified from sera of alpacas immunized with Spike protein and RBD using a phage display technique (Pymm et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Spike protein Spike variant Cryo-EM Crystallization Biophysical assay Animal model In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; crystallization; cryo-EM; C57BL/6J mice; SARS-CoV-2 strain hCoV-19/Australia/VIC01/2020; SARS-CoV-2 strain hCoV-19/Australia/VIC2089/2020 9.41

The nanobody construct potently neutralized SARS-CoV-2 in vitro. It displayed binding of E484K or N501Y variants of Spike protein. It also inhibited RBD binding to ACE2. Prophylactic administration of the nanobody construct significantly reduced viral loads in mice in a viral challenge.

 Apr/23/2021
Export (.csv)